JP2023513298A - 尿路上皮癌を治療するためのｆｇｆｒチロシンキナーゼ阻害剤及び抗ｐｄ１剤 - Google Patents

尿路上皮癌を治療するためのｆｇｆｒチロシンキナーゼ阻害剤及び抗ｐｄ１剤 Download PDF

Info

Publication number
JP2023513298A
JP2023513298A JP2022548573A JP2022548573A JP2023513298A JP 2023513298 A JP2023513298 A JP 2023513298A JP 2022548573 A JP2022548573 A JP 2022548573A JP 2022548573 A JP2022548573 A JP 2022548573A JP 2023513298 A JP2023513298 A JP 2023513298A
Authority
JP
Japan
Prior art keywords
dose
administered
antibody
weeks
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022548573A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023513298A5 (https=
Inventor
モンガ，マニッシュ
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2023513298A publication Critical patent/JP2023513298A/ja
Publication of JP2023513298A5 publication Critical patent/JP2023513298A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2022548573A 2020-02-12 2021-02-11 尿路上皮癌を治療するためのｆｇｆｒチロシンキナーゼ阻害剤及び抗ｐｄ１剤 Withdrawn JP2023513298A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202062975526P 2020-02-12 2020-02-12
US62/975,526 2020-02-12
US202063025817P 2020-05-15 2020-05-15
US63/025,817 2020-05-15
US202063055187P 2020-07-22 2020-07-22
US63/055,187 2020-07-22
US202063078205P 2020-09-14 2020-09-14
US63/078,205 2020-09-14
US202063078736P 2020-09-15 2020-09-15
US63/078,736 2020-09-15
US202063083316P 2020-09-25 2020-09-25
US63/083,316 2020-09-25
PCT/EP2021/053384 WO2021160763A1 (en) 2020-02-12 2021-02-11 Fgfr tyrosine kinase inhibitors and anti-pd1 agents for the treatment of urothelial carcinoma

Publications (2)

Publication Number Publication Date
JP2023513298A true JP2023513298A (ja) 2023-03-30
JP2023513298A5 JP2023513298A5 (https=) 2024-02-21

Family

ID=74666674

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022548573A Withdrawn JP2023513298A (ja) 2020-02-12 2021-02-11 尿路上皮癌を治療するためのｆｇｆｒチロシンキナーゼ阻害剤及び抗ｐｄ１剤

Country Status (15)

Country Link
US (1) US20230135136A1 (https=)
EP (1) EP4103184A1 (https=)
JP (1) JP2023513298A (https=)
KR (1) KR20220140777A (https=)
CN (1) CN115087446A (https=)
AU (1) AU2021219948A1 (https=)
BR (1) BR112022015825A2 (https=)
CA (1) CA3163407A1 (https=)
IL (1) IL295515A (https=)
JO (1) JOP20220181A1 (https=)
MX (1) MX2022009904A (https=)
PH (1) PH12022552091A1 (https=)
TW (1) TWI900527B (https=)
UY (1) UY39080A (https=)
WO (1) WO2021160763A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025046898A1 (ja) * 2023-08-31 2025-03-06 大鵬薬品工業株式会社 ３，５－二置換ベンゼンアルキニル化合物と免疫チェックポイント阻害薬を含む癌治療法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115925954A (zh) * 2022-12-28 2023-04-07 广州誉衡生物科技有限公司 抗-pd-1抗体及其在制备治疗尿路上皮癌患者的药物中的用途
EP4719420A1 (en) * 2023-05-24 2026-04-08 Janssen Pharmaceutica NV Treatment of locally advanced or metastatic urothelial carcinoma with erdafinitib

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018511611A (ja) * 2015-04-03 2018-04-26 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 癌治療のためのｆｇｆｒ／ｐｄ−１併用療法
WO2018141921A1 (en) * 2017-02-06 2018-08-09 Janssen Pharmaceutica Nv Cancer treatment
WO2019142149A2 (en) * 2018-01-22 2019-07-25 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-pd-1 antibodies

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
EP0951541B1 (en) 1995-07-31 2005-11-30 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
BRPI0611375A2 (pt) 2005-05-23 2010-08-31 Novartis Ag formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
JP2012505654A (ja) 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
KR102470456B1 (ko) 2014-09-26 2022-11-23 얀센 파마슈티카 엔.브이. Fgfr 억제제를 사용한 치료에 반응할 암 환자를 확인하는 데 있어서 fgfr 돌연변이 유전자 패널의 사용
KR102662228B1 (ko) * 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
PE20181326A1 (es) 2015-11-03 2018-08-20 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y sus usos
MX2018006181A (es) * 2015-11-23 2018-09-24 Five Prime Therapeutics Inc Inhibidores de fgfr2 solos o en combinacion con agentes que estimulan el sistema inmunitario en el tratamiento contra el cancer.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018511611A (ja) * 2015-04-03 2018-04-26 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 癌治療のためのｆｇｆｒ／ｐｄ−１併用療法
WO2018141921A1 (en) * 2017-02-06 2018-08-09 Janssen Pharmaceutica Nv Cancer treatment
WO2019142149A2 (en) * 2018-01-22 2019-07-25 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-pd-1 antibodies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EXP. REV. CLIN. PHARMACOL., vol. 13, no. 1, JPN6025003712, 2019, pages 1 - 6, ISSN: 0005520009 *
N. ENGL. J. MED., vol. 381;4, JPN6025003714, 2019, pages 338 - 348, ISSN: 0005520007 *
RECORD HISTORY OF NCT03473743, JPN6025003713, January 2020 (2020-01-01), ISSN: 0005520008 *
昭和学士会誌, vol. 76巻2号, JPN6025003715, 2016, pages 108 - 115, ISSN: 0005520006 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025046898A1 (ja) * 2023-08-31 2025-03-06 大鵬薬品工業株式会社 ３，５－二置換ベンゼンアルキニル化合物と免疫チェックポイント阻害薬を含む癌治療法
WO2025046973A1 (ja) * 2023-08-31 2025-03-06 大鵬薬品工業株式会社 ３，５－二置換ベンゼンアルキニル化合物と免疫チェックポイント阻害薬を含む癌治療法
WO2025047922A1 (ja) * 2023-08-31 2025-03-06 大鵬薬品工業株式会社 ３，５－二置換ベンゼンアルキニル化合物と免疫チェックポイント阻害薬を含む癌治療法

Also Published As

Publication number Publication date
US20230135136A1 (en) 2023-05-04
TWI900527B (zh) 2025-10-11
TW202140012A (zh) 2021-11-01
CA3163407A1 (en) 2021-08-19
CN115087446A (zh) 2022-09-20
IL295515A (en) 2022-10-01
JOP20220181A1 (ar) 2023-01-30
BR112022015825A2 (pt) 2022-10-04
MX2022009904A (es) 2022-08-25
KR20220140777A (ko) 2022-10-18
PH12022552091A1 (en) 2023-11-20
UY39080A (es) 2021-10-29
AU2021219948A1 (en) 2022-10-06
WO2021160763A1 (en) 2021-08-19
EP4103184A1 (en) 2022-12-21

Similar Documents

Publication Publication Date Title
US12398209B2 (en) Methods of treating cancers with antagonistic anti-PD-1 antibodies
CA3127388A1 (en) Combined pharmaceutical composition for treating tumor
TWI900527B (zh) 用於治療尿路上皮癌的ｆｇｆｒ酪胺酸激酶抑制劑和抗ｐｄ１藥劑
CN110494161A (zh) 用于治疗癌症的抗pd-l1抗体和dna-pk抑制剂的组合
EP3939610A1 (en) Combined pharmaceutical composition for treating small cell lung cancer
JP7749667B2 (ja) 肺がんを治療するためのｋｒａｓｇ１２ｃ阻害剤及びｐｄ－ｌ１結合アンタゴニストを含む方法及び組成物
JP2024529451A (ja) がんを治療するための方法及び組成物
TW202541838A (zh) 抗ｃｄ３８抗體在治療新診斷的多發性骨髓瘤中之用途
US20230321087A1 (en) Fgfr inhibitor combination therapies
HK40081114A (en) Fgfr tyrosine kinase inhibitors and anti-pd1 agents for the treatment of urothelial carcinoma
JP2024518612A (ja) 進行性固形腫瘍の治療のためのｆｇｆｒチロシンキナーゼ阻害剤
JP2024516970A (ja) 抗ｉｌ－２７抗体及びその使用
HK40113732A (zh) 包含shp2抑制剂和pd-l1结合拮抗剂的方法和组合物
HK40109234A (zh) 用於治疗癌症的方法和组合物
JP2025516649A (ja) Ｓｈｐ２阻害剤およびｐｄ－ｌ１結合アンタゴニストを含む方法および組成物
TW202402791A (zh) 抗ｉｌ－２７抗體之用途
CN114432438A (zh) 喹啉衍生物与pd-1单抗的药物组合

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250502

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250801

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260304

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20260330